Replimune Group, Inc. $REPL Shares Sold by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. cut its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL) by 46.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 133,800 shares of the company’s stock after selling 113,965 shares during the quarter. Nan Fung Trinity HK Ltd. owned about 0.14% of Replimune Group worth $1,772,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. purchased a new position in Replimune Group during the third quarter worth about $64,000. Vise Technologies Inc. acquired a new stake in shares of Replimune Group during the third quarter valued at about $163,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Replimune Group by 30.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,191 shares of the company’s stock valued at $223,000 after acquiring an additional 4,050 shares during the period. Maxi Investments CY Ltd purchased a new stake in shares of Replimune Group in the 3rd quarter valued at approximately $556,000. Finally, Opaleye Management Inc. purchased a new stake in shares of Replimune Group in the 2nd quarter valued at approximately $15,332,000. 92.53% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Replimune Group

In related news, CFO Emily Hill sold 9,256 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $14.28, for a total transaction of $132,175.68. Following the sale, the chief financial officer directly owned 215,852 shares of the company’s stock, valued at $3,082,366.56. This represents a 4.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Joseph P. Slattery sold 5,200 shares of the stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $21.80, for a total transaction of $113,360.00. Following the sale, the director owned 1,467 shares in the company, valued at approximately $31,980.60. This trade represents a 78.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 35,956 shares of company stock worth $654,036. Corporate insiders own 5.40% of the company’s stock.

Replimune Group Price Performance

NASDAQ REPL opened at $21.98 on Friday. The company has a quick ratio of 6.90, a current ratio of 7.11 and a debt-to-equity ratio of 0.59. The stock has a 50-day moving average of $14.63 and a two-hundred day moving average of $9.97. Replimune Group, Inc. has a 1-year low of $1.50 and a 1-year high of $23.54.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Wednesday, October 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.24. On average, sell-side analysts anticipate that Replimune Group, Inc. will post -2.40 earnings per share for the current fiscal year.

Analysts Set New Price Targets

REPL has been the subject of a number of research analyst reports. Piper Sandler raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. boosted their target price on Replimune Group from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, August 26th. Wall Street Zen raised Replimune Group from a “sell” rating to a “hold” rating in a research report on Saturday, October 31st. Wedbush upgraded Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price target on the stock in a research note on Friday, August 7th. Finally, Leerink Partners raised their price target on Replimune Group from $19.00 to $31.00 and gave the stock an “outperform” rating in a research report on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Replimune Group has an average rating of “Moderate Buy” and a consensus price target of $14.33.

About Replimune Group

Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.